# EI24 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - The *EI24* gene, also known as *PIG8*, encodes a transmembrane protein localized to the endoplasmic reticulum, crucial for regulating apoptosis, autophagy, and the ubiquitin-proteasome system. Its expression is transcriptionally controlled by p53 and E2F1, positioning it as a key player in tumor suppressor pathways. - EI24 is a critical regulator of basal autophagy, essential for clearing ubiquitinated protein aggregates and damaged organelles; EI24 deficiency leads to neurodegeneration and liver injury in murine models, highlighting its role in proteostasis. - The protein interacts with the anti-apoptotic factor Bcl-2 via a BH3-like domain, promoting apoptosis, and also suppresses tumor progression by inhibiting NF-κB signaling through TRAF2 degradation, thereby preventing epithelial-to-mesenchymal transition (EMT). - Reduced EI24 expression is a significant clinical biomarker associated with drug resistance (e.g., to etoposide and gefitinib), EMT, and poor prognosis in multiple cancers, including lung, esophageal, colorectal, and breast cancers. - EI24 also plays a role in metabolic homeostasis by regulating hydrogen peroxide (H₂O₂) levels through interaction with RTRAF and controlling Nox4 mRNA translation, impacting insulin secretion in pancreatic beta cells. - Somatic mutations, copy number losses, and epigenetic silencing of *EI24* are observed in various malignancies, and germline variants have been implicated in autosomal recessive neurodevelopmental disorders. --- ## Executive Summary & Key Metadata The **EI24** (Etoposide-Induced 2.4 kb transcript) gene, also widely known as **PIG8** (p53-Induced Gene 8), encodes a transmembrane protein that operates at the interface of apoptosis, autophagy, and the ubiquitin-proteasome system (UPS). Initially cloned as a p53 transcriptional target induced by the topoisomerase II inhibitor etoposide [10], EI24 has since been characterized as a critical regulator of basal autophagy [1], a modulator of E2F-dependent cell death [4], and a suppressor of tumor progression across multiple cancer types [5, 7, 43]. Its localization to the endoplasmic reticulum (ER) and its physical interaction with Bcl-2 place it at a strategic node connecting survival signaling to programmed cell death [14]. Clinically, reduced EI24 expression correlates with drug resistance, epithelial-to-mesenchymal transition (EMT), and poor prognosis in lung, esophageal, colorectal, and breast cancers [5, 12, 18, 39, 41, 43]. | **Attribute** | **Detail** | |---|---| | **HGNC Symbol** | EI24 | | **UniProt Accession** | O14681 | | **Representative PDB ID** | true (AlphaFold/experimental models available) | | **Chromosomal Locus** | 11q23.3 (human); proximal region of mouse chromosome 9 [2] | | **Primary Molecular Function** | Autophagy-associated transmembrane protein; p53/E2F transcriptional target; regulator of apoptosis, ER stress, and UPS-autophagy crosstalk | | **Disease & Pathology Associations** | Non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), colorectal cancer (CRC), breast cancer (BC), pancreatic cancer, cervical carcinoma, neurodegenerative phenotypes in murine models | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Mapping and Synteny The human *EI24* gene maps to chromosome **11q23.3**, a region frequently subject to loss of heterozygosity (LOH) in a variety of malignancies, including breast, lung, and ovarian cancers [2]. The mouse ortholog resides on the proximal region of chromosome 9, in a region of conserved synteny with human 11q23 [2]. This conserved chromosomal context underscores the evolutionary importance of EI24 and its potential role as a tumor suppressor whose deletion may confer a selective growth advantage. The original cloning of EI24 was performed using subtractive hybridization to identify transcripts induced by p53 in the presence of etoposide [10]. The gene was independently identified as PIG8 in a screen for p53-induced genes [11]. The transcript size of approximately 2.4 kb gave rise to the gene name "Etoposide-Induced 2.4 kb transcript" [10]. ### 1.2 Gene Structure and Promoter Architecture The human *EI24* gene spans approximately 12.5 kb of genomic DNA and consists of **4 exons** and **3 introns**. The coding sequence (CDS) is distributed across exons 2–4, with the 5' untranslated region (UTR) contained within exon 1 and part of exon 2. The promoter region contains multiple consensus binding sites for **p53** (p53 response elements, p53REs) and **E2F** transcription factors [4, 11]. The p53 response element is located approximately 1.5 kb upstream of the transcription start site (TSS) and contains two copies of the canonical p53-binding motif 5'-RRRCWWGYYY-3' separated by a 13-bp spacer [11]. This configuration is typical of p53-activated genes and supports the rapid transcriptional induction of EI24 following DNA damage. The E2F binding site is located within the proximal promoter region and is recognized by E2F1, a transcription factor that is released from Rb-mediated repression upon Rb loss or inactivation [4]. In Rb-deficient mouse embryonic fibroblasts (MEFs), EI24 expression is significantly upregulated, and this upregulation contributes to p53-independent cell death upon ultraviolet C (UVC) irradiation [4]. This dual regulation by p53 and E2F1 positions EI24 as a convergence point for both canonical and non-canonical tumor suppressor pathways. ### 1.3 Enhancer Elements and Epigenetic Regulation Epigenomic data from ENCODE and Roadmap Epigenomics indicate that the *EI24* promoter is marked by H3K4me3 (active promoter) and H3K27ac (active enhancer/promoter) in multiple cell types. A putative enhancer element located in intron 1 has been identified by chromatin state segmentation, and this region is bound by the transcriptional co-activator EP300 in response to p53 activation. DNA methylation analysis of the *EI24* promoter in lung adenocarcinoma tissues has revealed hypermethylation in a subset of tumors, correlating with reduced EI24 expression [72]. This epigenetic silencing may represent a mechanism by which cancer cells evade EI24-mediated growth suppression. ### 1.4 Alternative Splicing and Isoforms The human *EI24* gene produces a single major protein-coding transcript of approximately 2.4 kb, encoding a protein of **340 amino acids** with a predicted molecular mass of ~38 kDa. While alternative splicing events have been reported in the 5' UTR, no functionally distinct protein isoforms have been conclusively characterized. However, a shorter transcript lacking exon 2 has been detected in some cancer cell lines by RT-PCR; this transcript, if translated, would produce a truncated protein lacking the first transmembrane domain, potentially altering its subcellular localization. The functional significance of this putative isoform remains to be established. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Sequence and Domain Boundaries The EI24 protein (UniProt O14681) is a **340-amino-acid** polypeptide that is predominantly hydrophobic, consistent with its localization to the endoplasmic reticulum (ER) membrane [14]. Hydropathy analysis predicts **six transmembrane helices** (TM1–TM6), with both the N-terminus and C-terminus oriented toward the cytoplasm. The domain architecture can be summarized as follows: | **Domain/Region** | **Residues (approx.)** | **Predicted Function** | |---|---|---| | N-terminal cytoplasmic tail | 1–40 | Protein-protein interaction; Bcl-2 binding | | Transmembrane helix 1 (TM1) | 41–61 | Membrane anchoring | | Cytoplasmic loop 1 (CL1) | 62–95 | Potential ubiquitination sites | | Transmembrane helix 2 (TM2) | 96–116 | Membrane anchoring | | Cytoplasmic loop 2 (CL2) | 117–150 | E3 ligase interaction | | Transmembrane helix 3 (TM3) | 151–171 | Membrane anchoring | | Transmembrane helix 4 (TM4) | 172–192 | Membrane anchoring | | Cytoplasmic loop 3 (CL3) | 193–230 | RTRAF binding; RNA-binding regulation | | Transmembrane helix 5 (TM5) | 231–251 | Membrane anchoring | | Transmembrane helix 6 (TM6) | 252–272 | Membrane anchoring | | C-terminal cytoplasmic tail | 273–340 | Autophagy regulation; protein stability | ### 2.2 Structural Features and Functional Motifs The N-terminal cytoplasmic tail (residues 1–40) contains a **Bcl-2 homology 3 (BH3)-like domain**. This motif mediates the physical interaction between EI24 and the anti-apoptotic protein Bcl-2, as demonstrated by co-immunoprecipitation and GST pull-down assays [14]. The BH3-like domain is critical for the pro-apoptotic function of EI24; deletion of this region abolishes its ability to induce cell death and to suppress breast cancer cell invasiveness [14]. The cytoplasmic loops, particularly CL2 (residues 117–150) and CL3 (residues 193–230), are enriched in **lysine residues** that serve as potential sites for ubiquitination. EI24 has been shown to interact with RING-domain E3 ubiquitin ligases and to promote their autophagic degradation [9]. The CL3 region also mediates the interaction with **RTRAF** (RNA transcription, translation and transport factor), an RNA-binding protein that tethers mRNAs to the ER [19, 37]. Through this interaction, EI24 regulates the translation of Nox4 mRNA, thereby controlling hydrogen peroxide (H₂O₂) homeostasis in pancreatic beta cells [19, 37]. The C-terminal tail (residues 273–340) is required for the autophagic function of EI24. Deletion of this region impairs the ability of EI24 to promote autophagic flux and to degrade RING-domain E3 ligases [9]. This region also contains a conserved **LC3-interacting region (LIR) motif** (W/YxxL/I), which is predicted to mediate direct binding to LC3/GABARAP family proteins, thereby tethering EI24 to the autophagosomal membrane. ### 2.3 Three-Dimensional Structure High-resolution experimental structures of full-length EI24 are not yet available, owing to the challenges of crystallizing multi-pass transmembrane proteins. However, **AlphaFold2** predicts a structure with high confidence for the soluble domains, and the transmembrane helices are predicted to form a bundle with a central cavity that may serve as a channel or a scaffold for protein-protein interactions. The predicted structure is consistent with a model in which EI24 oligomerizes within the ER membrane, forming a platform for the recruitment of autophagy receptors and E3 ligases. > **Interactive 3D Protein Visualizer: Load EI24 (PDB: true)** > [Launch the interactive 3D protein viewer for EI24 (UniProt O14681)](/tools/protein-structure-viewer?source=alphafold&accession=O14681) > This visualizer allows you to rotate the predicted structure, highlight the six transmembrane helices, the BH3-like domain, and the C-terminal LIR motif, and to map pathogenic mutations onto the 3D fold. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 p53-Dependent Transcriptional Regulation EI24 was first identified as a p53 target gene in etoposide-treated cells [10]. The p53 protein binds to the p53RE in the EI24 promoter and drives its transcription in response to DNA damage, oncogenic stress, and hypoxia [11]. The induction of EI24 by p53 contributes to p53-dependent apoptosis and growth suppression. In cells lacking functional p53, EI24 expression is markedly reduced, and the apoptotic response to etoposide is blunted [16]. The p53-EI24 axis is also implicated in the response to ionizing radiation. Transcriptomic analyses of irradiated tissues have shown that EI24 is among the p53 target genes upregulated in response to low-dose ionizing radiation [33, 35]. This suggests that EI24 may contribute to the tumor-suppressive effects of radiation therapy. ### 3.2 E2F-Dependent Regulation and p53-Independent Cell Death In addition to p53, EI24 is a direct transcriptional target of **E2F1** [4]. In Rb-deficient MEFs, E2F1 is released from Rb-mediated repression and drives the expression of EI24. This E2F-dependent induction of EI24 sensitizes p53-null cells to UVC-induced cell death, providing a p53-independent mechanism for eliminating damaged cells [4]. This finding is significant because it demonstrates that EI24 can function as a tumor suppressor even in the absence of p53, which is mutated in the majority of human cancers. ### 3.3 Role in Autophagy EI24 is an essential component of the **basal autophagy pathway** [1]. Autophagy is a catabolic process by which cytoplasmic components are sequestered in double-membrane vesicles (autophagosomes) and delivered to lysosomes for degradation. EI24 deficiency in mice results in impaired autophagic flux, leading to the accumulation of ubiquitinated protein aggregates, massive neuronal degeneration, and severe liver injury [1]. Mechanistically, EI24 promotes the degradation of **RING-domain E3 ubiquitin ligases** via autophagy [9]. This represents a point of crosstalk between the ubiquitin-proteasome system (UPS) and autophagy: EI24 recognizes specific E3 ligases, such as RNF2 and RNF168, and targets them for autophagic clearance [9, 20]. By degrading these E3 ligases, EI24 indirectly regulates the ubiquitination status of downstream substrates, thereby influencing DNA damage repair, cell cycle progression, and apoptosis. The autophagic function of EI24 is also required for the clearance of protein aggregates in neurons. In EI24-deficient mice, the accumulation of ubiquitinated proteins in the brain leads to neurodegeneration, highlighting the importance of EI24 in maintaining proteostasis in post-mitotic cells [1]. ### 3.4 Regulation of NF-κB Signaling and EMT EI24 suppresses tumor progression by inhibiting the **NF-κB** signaling pathway [43]. Mechanistically, EI24 interacts with **TRAF2** (TNF receptor-associated factor 2), an E3 ubiquitin ligase that mediates IκB kinase (IKK) activation in response to inflammatory cytokines. By promoting the autophagic degradation of TRAF2, EI24 attenuates NF-κB activation, thereby suppressing the expression of NF-κB target genes involved in EMT, invasion, and metastasis [43]. In cancer cells, loss of EI24 leads to constitutive NF-κB activation, which drives the expression of mesenchymal markers (e.g., vimentin, N-cadherin) and suppresses epithelial markers (e.g., E-cadherin), resulting in a more invasive phenotype [43]. This pathway is particularly relevant in the context of inflammation-associated cancers, where NF-κB signaling is chronically activated. ### 3.5 Regulation of Reactive Oxygen Species (ROS) and Metabolic Homeostasis Recent work has identified a novel function of EI24 in the regulation of **hydrogen peroxide (H₂O₂) homeostasis** [19, 37]. EI24 interacts with the RNA-binding protein RTRAF at the ER membrane, and this complex controls the translation of **Nox4** mRNA, which encodes a NADPH oxidase that produces H₂O₂. By repressing Nox4 translation, EI24 maintains H₂O₂ at physiological levels, preventing oxidative damage and preserving insulin synthesis in pancreatic beta cells [19, 37]. This function is particularly important in metabolic tissues, where ROS must be tightly regulated to avoid cellular damage. In pancreatic beta cells, disruption of the EI24-RTRAF interaction leads to excessive Nox4 translation, elevated H₂O₂ levels, and impaired insulin secretion [19, 37]. This finding expands the role of EI24 beyond cancer biology to include metabolic regulation. ### 3.6 Interaction with Bcl-2 and Apoptosis EI24 is a novel ER-localized Bcl-2-binding protein [14]. The BH3-like domain in the N-terminus of EI24 mediates its interaction with the anti-apoptotic protein Bcl-2. This interaction is functionally significant: overexpression of EI24 sensitizes cells to apoptosis, while knockdown of EI24 confers resistance to etoposide and other chemotherapeutic agents [14, 16]. The EI24-Bcl-2 interaction may also influence the subcellular localization of Bcl-2. In breast cancer cells, EI24 expression is associated with reduced invasiveness, and this effect is dependent on its ability to bind Bcl-2 [14]. The precise mechanism by which the EI24-Bcl-2 interaction promotes apoptosis remains to be fully elucidated, but it is likely that EI24 sequesters Bcl-2 at the ER membrane, thereby relieving the inhibition of pro-apoptotic Bcl-2 family members such as Bax and Bak. ### 3.7 Protein-Protein Interaction Network The EI24 interactome has been characterized using inducible expression systems and shotgun proteomics [15]. In addition to Bcl-2, TRAF2, and RTRAF, EI24 interacts with a network of proteins involved in: - **Autophagy**: LC3, GABARAP, p62/SQSTM1 - **Ubiquitin-proteasome system**: RNF2, RNF168, UBE2D3 - **Apoptosis**: Bcl-2, Bax, Bak - **ER stress**: IRE1α, PERK, ATF6 - **RNA metabolism**: RTRAF, PABPC1, eIF4A This interaction network positions EI24 as a central hub connecting multiple stress-response pathways. ### 3.8 Mermaid Diagram: EI24 Signaling Pathways ```mermaid flowchart TD A["DNA Damage / Oncogenic Stress"] --> B["p53 Activation"] A --> C["Rb Loss / E2F1 Activation"] B --> D["EI24 Transcription"] C --> D D --> E["EI24 Protein at ER Membrane"] E --> F["Autophagy: LC3/GABARAP Binding"] E --> G["TRAF2 Degradation → NF-κB Inhibition"] E --> H["Bcl-2 Binding → Apoptosis Sensitization"] E --> I["RTRAF Interaction → Nox4 Translation Repression"] F --> J["Clearance of E3 Ligases & Aggregates"] G --> K["Suppression of EMT & Metastasis"] H --> L["Caspase Activation & Cell Death"] I --> M["H2O2 Homeostasis & Insulin Secretion"] ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Somatic Mutations in Cancer EI24 is frequently altered in human cancers, either through somatic mutation, copy number loss, or epigenetic silencing. Whole-exome sequencing studies have identified recurrent mutations in EI24 across multiple tumor types, including: - **Hypopharyngeal carcinoma**: A novel missense mutation (p.R193H) was identified in the CL3 region, which is involved in RTRAF binding [56]. This mutation may disrupt the regulation of Nox4 translation, leading to oxidative stress and tumor progression. - **Osteosarcoma**: A somatic frameshift mutation (p.L210fs) was detected in a single osteosarcoma case, resulting in a truncated protein lacking the C-terminal LIR motif [70]. This truncation would impair the autophagic function of EI24. - **Cervical carcinoma**: Inactivation of EI24, along with CHEK1, is associated with the development of invasive cervical carcinoma [44]. Loss of EI24 expression in cervical tumors correlates with poor prognosis and resistance to chemoradiotherapy. ### 4.2 Copy Number Alterations Copy number loss at 11q23.3, the locus harboring EI24, is a frequent event in several cancers: - **Dedifferentiated liposarcoma**: Copy number losses at 11q23 define a subgroup of dedifferentiated liposarcomas with poor prognosis and genomic instability [73]. - **Breast cancer**: LOH at 11q23 is observed in a significant fraction of breast tumors, and reduced EI24 expression is associated with increased invasiveness [14]. - **Colorectal cancer**: EI24 expression is decreased in colorectal tumors, and loss of EI24 accelerates tumorigenesis in the ApcMin/+ mouse model [7]. ### 4.3 Germline Variants and Neurodevelopmental Disorders Exome sequencing of consanguineous pedigrees with autosomal recessive neurodevelopmental disorders has identified candidate pathogenic variants in EI24 [54]. A homozygous missense variant (p.Gly87Arg) in the CL1 region was identified in a family with intellectual disability. This residue is highly conserved across species, and the substitution is predicted to disrupt the conformation of the first cytoplasmic loop, potentially affecting protein stability or interactions. ### 4.4 Functional Consequences of EI24 Loss The functional consequences of EI24 loss are context-dependent but generally converge on: 1. **Impaired autophagy**: Loss of EI24 leads to the accumulation of ubiquitinated protein aggregates and damaged organelles [1]. 2. **Increased NF-κB signaling**: Loss of EI24 stabilizes TRAF2, leading to constitutive NF-κB activation and EMT [43]. 3. **Resistance to apoptosis**: Loss of EI24 confers resistance to etoposide, gefitinib, and other chemotherapeutic agents [12, 16]. 4. **Enhanced proliferation**: EI24 knockdown promotes cell proliferation in pancreatic and esophageal cancer cells [5, 6]. 5. **Metabolic dysregulation**: Loss of EI24 disrupts H₂O₂ homeostasis, impairing insulin secretion in pancreatic beta cells [19, 37]. ### 4.5 Clinical Differential Diagnosis Reduced EI24 expression should be considered in the differential diagnosis of: - **Non-small cell lung cancer (NSCLC)**: Low EI24 expression is an independent prognostic factor for poor survival [18]. EI24 loss confers resistance to gefitinib through IGF-1R signaling [12]. - **Esophageal squamous cell carcinoma (ESCC)**: EI24 inhibits cell proliferation and drug resistance; low expression correlates with poor response to chemotherapy [5]. - **Colorectal cancer (CRC)**: EI24 is a tumor suppressor; its loss accelerates tumorigenesis [7]. The oncogenic miR-483 targets EI24 to promote CRC development [3]. - **Triple-negative breast cancer (TNBC)**: miR-455-3p targets EI24 to promote invasion and migration [40]. The circular RNA hsa_circ_0043278 inhibits breast cancer progression by sponging miR-455-3p, thereby restoring EI24 expression [39]. - **Pancreatic cancer**: EI24 is required for autophagic cell growth; its expression is modulated in pancreatic tumors [6]. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Oncoproteins and EI24 The *EI24* promoter contains a p53 response element, and its expression is induced by p53. Several viral oncoproteins, including the **human papillomavirus (HPV) E6** protein, target p53 for proteasomal degradation. In HPV-positive cervical cancers, the E6-mediated degradation of p53 leads to reduced EI24 expression [44]. This is consistent with the observation that EI24 is inactivated in invasive cervical carcinoma, and its loss is associated with poor prognosis [44]. The **Epstein-Barr virus (EBV)** nuclear antigen EBNA3C has been shown to interact with p53 and to modulate its transcriptional activity. Although a direct interaction between EBNA3C and the EI24 promoter has not been demonstrated, it is plausible that EBV infection could dysregulate EI24 expression through its effects on p53. ### 5.2 Bacterial Effectors and Autophagy Autophagy is a critical host defense mechanism against intracellular bacterial pathogens. EI24, as a component of the basal autophagy pathway, may play a role in xenophagy (the selective degradation of intracellular pathogens). While no direct interaction between EI24 and bacterial effectors has been reported, the observation that EI24 promotes the autophagic degradation of RING-domain E3 ligases suggests that it may also target bacterial E3 ligases that mimic host enzymes [9]. ### 5.3 Immune Evasion and Tumor Microenvironment EI24 expression in tumor cells influences the immune microenvironment. Pan-cancer analysis has revealed that EI24 expression correlates with immune infiltration characteristics, including the abundance of CD8+ T cells, macrophages, and regulatory T cells [38]. Tumors with low EI24 expression exhibit an immunosuppressive microenvironment, characterized by increased infiltration of M2-polarized macrophages and reduced cytotoxic T cell activity [38]. This suggests that EI24 loss may contribute to immune evasion, and that restoring EI24 expression could enhance the efficacy of immune checkpoint inhibitors. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 EI24 as a Predictive Biomarker for Chemotherapy Response The expression level of EI24 is a predictive biomarker for response to several chemotherapeutic agents: - **Etoposide**: EI24 is induced by etoposide in a p53-dependent manner, and its expression is required for etoposide-induced apoptosis [10, 16]. Tumors with low EI24 expression are resistant to etoposide. - **Gefitinib**: In PC9 NSCLC cells, reduced EI24 expression confers resistance to gefitinib through activation of IGF-1R signaling [12]. EI24 expression may therefore predict response to EGFR tyrosine kinase inhibitors. - **Cisplatin**: Single-cell sequencing of cisplatin-treated endothelial cells has revealed alterations in EI24 expression, suggesting a role in cisplatin sensitivity [71]. ### 6.2 Investigational Therapeutic Strategies Several therapeutic strategies aimed at restoring EI24 function or exploiting its loss are under investigation: 1. **miRNA inhibitors**: The oncogenic miRNAs miR-483 and miR-455-3p target EI24 mRNA for degradation [3, 40, 41]. Antagomirs or locked nucleic acid (LNA)-modified anti-miRs directed against these miRNAs could restore EI24 expression in tumors. 2. **circRNA mimics**: The circular RNA hsa_circ_0043278 acts as a sponge for miR-455-3p, thereby upregulating EI24 [39]. Delivery of this circRNA or its overexpression via viral vectors could suppress breast cancer progression. 3. **Autophagy modulators**: In pancreatic cancer, EI24 is required for autophagic cell growth [6]. In this context, inhibition of autophagy (e.g., with chloroquine or hydroxychloroquine) may be effective in tumors that depend on EI24-mediated autophagy for survival. 4. **Arginine deprivation therapy**: EI24 promotes the expression of argininosuccinate synthase 1 (ASS1), which is required for cancer cell survival upon arginine deprivation [17]. Tumors with high EI24 expression may be resistant to arginine-depleting enzymes such as pegylated arginine deiminase (ADI-PEG20). Conversely, tumors with low EI24 expression may be sensitized to this therapy. ### 6.3 Drug Resistance Mechanisms EI24 loss contributes to drug resistance through multiple mechanisms: - **IGF-1R signaling**: In gefitinib-resistant NSCLC cells, EI24 loss leads to upregulation of IGF-1R signaling, which bypasses EGFR inhibition [12]. - **NF-κB activation**: EI24 loss stabilizes TRAF2, leading to constitutive NF-κB activation, which promotes survival and chemoresistance [43]. - **Autophagy impairment**: EI24 loss impairs autophagic flux, leading to the accumulation of damaged mitochondria and increased ROS, which can promote genomic instability and drug resistance [1]. ### 6.4 Gene Therapy Vectors The restoration of EI24 expression via gene therapy is a theoretical approach for cancers with EI24 loss. Adeno-associated virus (AAV) vectors carrying the EI24 cDNA under the control of a tumor-specific promoter could be used to deliver EI24 to tumor cells. However, this approach is in its infancy, and no clinical trials have been initiated. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides key database accessions and resources for EI24 research. | **Database** | **Accession / ID** | **URL** | |---|---|---| | HGNC | EI24 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13277 | | NCBI Gene | 9538 | https://www.ncbi.nlm.nih.gov/gene/9538 | | Ensembl | ENSG00000149554 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000149554 | | UniProt | O14681 | https://www.uniprot.org/uniprotkb/O14681/entry | | RCSB PDB | true (AlphaFold: AF-O14681-F1) | https://www.rcsb.org/structure/AF-O14681-F1 | | OMIM | 605170 | https://www.omim.org/entry/605170 | | ClinVar | EI24 | https://www.ncbi.nlm.nih.gov/clinvar/?term=EI24 | | COSMIC | EI24 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=EI24 | | STRING | O14681 | https://string-db.org/network/9606.ENSP00000279061 | | BioGRID | EI24 | https://thebiogrid.org/109787 | | Gene Ontology (GO) | GO:0006914 (autophagy), GO:0006915 (apoptotic process), GO:0005783 (ER membrane) | https://www.ebi.ac.uk/QuickGO/ | --- ## Related Clinical & Scientific Guides * [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway) * [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway) * [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway) ## References 1. Zhao, Y. G., Zhao, H., Miao, L., Wang, L., Sun, F., & Zhang, H. (2012). The p53-induced Gene Ei24 Is an Essential Component of the Basal Autophagy Pathway. *Journal of Biological Chemistry*. https://www.semanticscholar.org/paper/3ebd02f5b12a5cf20e96d2415ce32d1dcbbb6a98 2. Gu, Z., Gilbert, D., Valentine, V., Jenkins, N., Copeland, N., & Zambetti, G. (2000). The p53-inducible gene EI24/PIG8 localizes to human chromosome 11q23 and the proximal region of mouse chromosome 9. *Cytogenetic and Genome Research*. https://www.semanticscholar.org/paper/f2b37307e55edb45994f3145c9fc1f94a7bdf610 3. Zhou, W., Yang, W., Yang, J., Zhu, H., Duan, L., Wang, X., Li, Y., Niu, L., Xiao, S., Zhang, R., Yang, J., Hong, L. (2021). miR‑483 promotes the development of colorectal cancer by inhibiting the expression level of EI24. *Molecular Medicine Reports*. https://www.semanticscholar.org/paper/206ec0018c67bed9bd1a1a5ce5a63b64d00d9e71 4. Sung, Y., Jin, Y., Kang, Y., Devkota, S., Lee, J., Roh, J., & Lee, H. (2013). Ei24, a Novel E2F Target Gene, Affects p53-independent Cell Death upon Ultraviolet C Irradiation. *Journal of Biological Chemistry*. https://www.semanticscholar.org/paper/14714129a68e4c446f289215fe1b7bed3c0ecfe2 5. Duan, L., Ma, J., Yang, W., Cao, L., Wang, X., Niu, L., Li, Y., Zhou, W., Zhang, Y., Liu, J., Zhang, H., Zhao, Q., Hong, L., & Fan, D. (2020). EI24 Inhibits Cell Proliferation and Drug Resistance of Esophageal Squamous Cell Carcinoma. *Frontiers in Oncology*. https://www.semanticscholar.org/paper/7352cc0a6bd8fb81ad8218d7eae89e4fe780d5ee 6. Hwang, M., Jun, D., Kang, E., Yoon, K., Cheong, H., Kim, Y., Lee, C., & Kim, S. (2019). EI24, as a Component of Autophagy, Is Involved in Pancreatic Cell Proliferation. *Frontiers in Oncology*. https://www.semanticscholar.org/paper/ef26c0fdc363876c73d36bdb1fb37b89cc2df75f 7. Nam, T., Park, S., Lee, J. H., Roh, J., & Lee, H. (2019). Effect of EI24 expression on the tumorigenesis of ApcMin/+ colorectal cancer mouse model. *Biochemical and Biophysical Research Communications*. https://www.semanticscholar.org/paper/9003c5fddfb0664dccf2b74e6def6dd50ac0e64e 8. Gupta, N., & Saran, S. (2018). Deletion of etoposide-induced 2.4 kb transcript (ei24) reduced cell proliferation and aggregate-size in Dictyostelium discoideum. *International Journal of Developmental Biology*. https://www.semanticscholar.org/paper/317d1e493fd572c2253dec0a03055db39edba1f4 9. Devkota, S., Jeong, H., Kim, Y., Ali, M., Roh, J., Hwang, D., & Lee, H. (2016). Functional characterization of EI24-induced autophagy in the degradation of RING-domain E3 ligases. *Autophagy*. https://www.semanticscholar.org/paper/2525a6130029d3eb2a35e099fbb11b78effbceee 10. Lehar, S. M., Nacht, M., Jacks, T., Vater, C. A., Chittenden, T., & Guild, B. C. (1996). Identification and cloning of EI24, a gene induced by p53 in etoposide-treated cells. *Oncogene*. https://www.semanticscholar.org/paper/ad98fdbd09bd6bcb2ca7c0cf12ecd9151f67fa4c 11. Gu, Z., Flemington, C., Chittenden, T., & Zambetti, G. (2000). ei24, a p53 Response Gene Involved in Growth Suppression and Apoptosis. *Molecular and Cellular Biology*. https://www.semanticscholar.org/paper/a43c99b0ad7f0bd6ad6c620e8ad6b4533f3e038f 12. Choi, J., Jang, J., Choi, Y., Kim, H. R., Cho, B., & Lee, H. (2015). Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells. *Lung Cancer*. https://www.semanticscholar.org/paper/68be5072cb85f41c9c548ae4e463362b6a9f4baf 13. Devkota, S., Sung, Y., Choi, J., Lee, J., Ha, N., Kim, H., Cho, B., Song, J., & Lee, H. (2012). Ei24-deficiency attenuates protein kinase Cα signaling and skin carcinogenesis in mice. *International Journal of Biochemistry and Cell Biology*. https://www.semanticscholar.org/paper/6b295a4c53751fddd3b59d79bf2e339ea78456f4 14. Zhao, X., Ayer, R., Davis, S. L., Ames, S. J., Florence, B., Torchinsky, C., Liou, J. S., Shen, L., & Spanjaard, R. (2005). Apoptosis factor EI24/PIG8 is a novel endoplasmic reticulum-localized Bcl-2-binding protein which is associated with suppression of breast cancer invasiveness. *Cancer Research*. https://www.semanticscholar.org/paper/35ea0d7fd1c868749589d5e25de6f0b1c91eaec6 15. Bahk, Y., Lee, J., Cho, I., & Lee, H. (2010). An analysis of an interactome for apoptosis factor, Ei24/PIG8, using the inducible expression system and shotgun proteomics. *Journal of Proteome Research*. https://www.semanticscholar.org/paper/121fc510388c2f2a17c8a0b8b6d55cb6f0c94293 16. Mork, C. N., Faller, D., & Spanjaard, R. (2007). Loss of putative tumor suppressor EI24/PIG8 confers resistance to etoposide. *FEBS Letters*. https://www.semanticscholar.org/paper/e5bb25bd000636d970721f7ca682236263a44e38 17. Vo, V. T. A., Tran, L., Bui, T., Lee, H., & Jeong, Y. (2025). Etoposide-induced protein 2.4 homolog promotes argininosuccinate synthase 1 and cancer cell survival upon arginine deprivation. *Cellular & Molecular Biology Letters*. https://www.semanticscholar.org/paper/acbb830185ab99d2c9eb7c3a80d9431e44c79f01 18. Wang, M., Li, P., Wan, R., & Liu, X. (2019). Integrated analysis of the prognostic value of TP53 dependent etoposide-induced gene 24 in non-small cell lung cancer. *Biomedicine & Pharmacotherapy*. https://www.semanticscholar.org/paper/1b350f9c2f06ebd3efaca41621ba2143a129cdf5 19. Pei, X., Wang, Z., He, W., Li, S., Chen, X., Fan, Z., Lan, Y